![a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram](https://www.researchgate.net/publication/301733304/figure/fig1/AS:479828383145984@1491411409128/a-KaplanMeier-relapse-free-survival-median-follow-up-time-42-months-of-all-cases-b.png)
a Kaplan?Meier relapse-free survival (median follow-up time 42 months)... | Download Scientific Diagram
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/2d946164-cd22-4ac0-b6fa-17e8eae70ab5/gr3_lrg.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2022/09/Figure-1-Post-hoc-analysis.-Overall-survival-landmarked-from-date-of-HSCT-940x419.jpg)
Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
![Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13014-014-0319-y/MediaObjects/13014_2014_319_Fig2_HTML.gif)
Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
![Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram](https://www.researchgate.net/publication/338589680/figure/fig1/AS:847421814878209@1579052513758/Kaplan-Meier-plot-of-overall-survival-Median-follow-up-was-213-months-range.png)
Kaplan-Meier plot of overall survival. Median follow-up was 21.3 months... | Download Scientific Diagram
![Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/7/75bb0160b856873819cdcefe4dc6072ed7ef267c.png)
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/0b732d25-37b7-4d93-ad0b-8f60f96a958e/gr1.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
![Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES](https://openwaterserverless.azurewebsites.net/api/imageconvert?url=https%3A%2F%2Fvo-general.s3.amazonaws.com%2F58ec95b2-ef6d-442b-b62e-3ccba8548e35%2Ff10505cb-3cc8-43bd-ac78-d554642072a8%3FAWSAccessKeyId%3DAKIAJ4PRWO26HAX3IOCA%26Expires%3D1702478222%26response-content-disposition%3Dinline%253B%2520filename%253D%252237.png%2522%26response-content-type%3Dimage%252Fpng%26Signature%3DuwFSs1h26CCYBhQ67vJDFkdpTpc%253D&width=640&height=480&color=white)
Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
![A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-09949-5/MediaObjects/41598_2022_9949_Fig1_HTML.png)